Frequent concomitant epigenetic silencing of the stress-responsive tumor suppressor gene CADM1, and its interacting partner DAL-1 in nasal NK/T-cell lymphoma

International Journal of Cancer

Volumn 124, Issue 7, 2009, Pages 1572-1578

  Fu, Li ^a   Gao, Zifen ^b   Zhang, Xiaohua ^b,c   Tsang, Ying Hung ^a   Goh, Hwee Koon ^a   Geng, Hua ^d   Shimizu, Norio ^e   Tsuchiyama, Junjiro ^f   Srivastava, Gopesh ^g   Tao, Qian ^a,d,h  

^a Johns Hopkins Singapore   (Singapore)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c YAN'AN UNIVERSITY   (China)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^f KAWASAKI MEDICAL SCHOOL   (Japan)

^g UNIVERSITY OF HONG KONG   (Hong Kong)

^h JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

CADM1; DAL 1; Methylation; Nasal lymphoma; Tumor suppressor gene

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA METHYLTRANSFERASE 1; PROTEIN; PROTEIN CADM1; PROTEIN DAL 1; UNCLASSIFIED DRUG; CADM1 PROTEIN, HUMAN; EPB41L3 PROTEIN, HUMAN; IMMUNOGLOBULIN; MEMBRANE PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CELL LINE; CHROMOSOME 11Q; CONTROLLED STUDY; DEMETHYLATION; EPIGENETICS; GENE; GENE DELETION; GENE INACTIVATION; GENE SILENCING; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; NATURAL KILLER CELL; NK T CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; STRESS; TUMOR SUPPRESSOR GENE; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOGLOBULINS; LYMPHOMA, EXTRANODAL NK-T-CELL; MEMBRANE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEINS;

EID: 61449219037     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24123     Document Type: Article

References (55)

1. Jaffe ES, Chan JK, Su IJ, Frizzera G, Mori S, Feller AC, Ho FC. Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996;20:103-11.
2. Ho FC, Srivastava G, Loke SL, Fu KH, Leung BP, Liang R, Choy D. Presence of Epstein-Barr virus DNA in nasal lymphomas of B and 'T cell type. Hematol Oncol 1990;8:271-81.
3. Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia 2005;19:2186-94.
4. Ng CS, Chan JK, Cheng PN, Szeto SC. Nasal T-cell lymphoma associated with hemophagocytic syndrome. Cancer 1986;58:67-71.
5. Ho FC, Todd D, Loke SL, Ng RP, Khoo RK. Clinico-pathological features of malignant lymphomas in 294 Hong Kong Chinese patients, retrospective study covering an eight-year period. Int J Cancer 1984;34:143-8.
6. Aozasa K, Ohsawa M, Tomita Y, Tagawa S, Yamamura T. Polymorphic reticulosis is a neoplasm of large granular lymphocytes with CD31 phenotype. Cancer 1995;75:894-901.
7. Arber DA, Weiss LM, Albujar PF, Chen YY, Jaffe ES. Nasal lymphomas in Peru. High incidence of. T-cell immunophenotype and. Epstein-Barr virus infection [see comments]. Am J Surg Pathol 1993;17:392-9.
8. Elenitoba-Johnson KS, Zarate-Osorno A, Meneses A, Krenacs L, Kingma DW, Raffeld M, Jaffe ES. Cytotoxic granular protein expression. Epstein-Barr virus strain type, and latent membrane protein-1 oncogene deletions in nasal. T-lymphocyte/natural killer cell lymphomas from. Mexico. Mod Pathol 1998;11:754-61.
9. Gaal K, Sun NC, Hernandez AM, Arber DA. Sinonasal NK/T-cell lymphomas in the United States. Am J Surg Pathol 2000;24:1511-17.
10. Tao Q, Young LS, Woodman CB, Murray PG. Epstein-Barr virus (EBV) and its associated human cancers-genetics, epigenetics, pathobiology and novel therapeutics. Front Biosci 2006;11:2672-713.
11. Minarovits J, Hu LF, Imai S, Harabuchi Y, Kataura A, Minarovits- Kormuta S, Osato T, Klein G. Clonality, expression and methylation patterns of the Epstein-Barr virus genomes in lethal midline granulo mas classified as peripheral angiocentric T cell lymphomas. J Gen Virol 1994;75:77-84.
12. Tao Q, Ho FC, Loke SL, Srivastava G. Epstein-Barr virus is localized in the tumour cells of nasal lymphomas of NK. T or B cell type. Int J Cancer 1995;60:315-20.
13. Chiang AK, Tao Q, Srivastava G, Ho FC. Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease. Int J Cancer 1996;68:285-90.
14. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
15. Siu LL, Chan JK, Wong KF, Kwong YL. Specific patterns of gene methylation in natural killer cell lymphomas: p73 is consistently involved. Am J Pathol 2002;160:59-66.
16. Murray PG, Qiu GH, Fu L, Waites ER, Srivastava G, Heys D, Agathanggelou A, Latif F, Grundy RG, Mann JR, Starczynski J, Crocker J, et al. Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma. Oncogene 2004;23:1326-31.
17. Kawamata N, Inagaki N, Mizumura S, Sugimoto KJ, Sakajiri S, Ohyanagi-Hara M, Oshimi K. Methylation status analysis of cell cycle regulatory genes (p16INK4A, p15INK4B, p21Waf1/Cip1, p27Kip1 and p73) in natural killer cell disorders. Eur J Haematol 2005;74:4244-9.
18. Ying J, Li H, Murray P, Gao Z, Chen YW, Wang Y, Lee KY, Chan AT, Ambinder RF, Srivastava G, Tao Q. Tumor-specific methylation of the 8p22 tumor suppressor gene DLC1 is an epigenetic biomarker for Hodgkin, nasal NK/T-cell and other types of lymphomas. Epigenetics 2007;2:15-21.
19. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001;1:157-62.
20. Siu LL, Wong KF, Chan JK, Kwong YL. Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent patterns of genetic alterations. Am J Pathol 1999;155:1419-25.
21. Siu LL, Chan V, Chan JK, Wong KF, Liang R, Kwong YL. Consistent patterns of allelic loss in natural killer cell lymphoma. Am J Pathol 2000;157:1803-9.
22. Wang SS, Virmani A, Gazdar AF, Minna JD, Evans GA. Refined mapping of two regions of loss of heterozygosity on chromosome band 11q23 in lung cancer. Genes Chromosomes Cancer 1999;25:154-9.
23. Connolly KC, Gabra H, Millwater CJ, Taylor KJ, Rabiasz GJ, Watson JE, Smyth JF, Wyllie AH, Jodrell DI. Identification of a region of frequent loss of heterozygosity at 11q24 in colorectal cancer. Cancer Res 1999;59:2806-9.
24. Negrini M, Rasio D, Hampton GM, Sabbioni S, Rattan S, Carter SL, Rosenberg AL, Schwartz GF, Shiloh Y, Cavenee WK, Croce CM. Definition and refinement of chromosome 11 regions of loss of heterozygosity in breast cancer: identification of a new region at 11q23.3. Cancer Res 1995;55:3003-7.
25. Mugica-Van Herckenrode C, Rodriguez JA, Iriarte-Campo V, Carracedo A, Barros F. Definition of a region of loss of heterozygosity at chromosome 11q in cervical carcinoma. Diagn Mol Pathol 1999;8:92-6.
26. Uzawa K, Suzuki H, Komiya A, Nakanishi H, Ogawara K, Tanzawa H, Sato K. Evidence for two distinct tumor-suppressor gene loci on the long arm of chromosome 11 in human oral cancer. Int J Cancer 1996;67:510-14.
27. Davis M, Hitchcock A, Foulkes WD, Campbell IG. Refinement of two chromosome 11q regions of loss of heterozygosity in ovarian cancer. Cancer Res 1996;56:741-4.
28. Harn HJ, Fan HC, Chen CJ, Tsai NM, Yen CY, Huang SC. Microsatellite alteration at chromosome 11 in primary human nasopharyngeal carcinoma in Taiwan. Oral Oncol 2002;38:23-9.
29. Pulido HA, Fakruddin MJ, Chatterjee A, Esplin ED, Beleno N, Martinez G, Posso H, Evans GA, Murty VV. Identification of a 6-cM minimal deletion at 11q23.1-23.2 and exclusion of PPP2R1B gene as a deletion target in cervical cancer. Cancer Res 2000;60:6677-82.
30. Savitsky K, Sfez S, Tagle DA, Ziv Y, Sartiel A, Collins FS, Shiloh Y, Rotman G. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum Mol Genet 1995;4:2025-32.
31. Wang SS, Esplin ED, Li JL, Huang L, Gazdar A, Minna J, Evans GA. Alterations of the PPP2R1B gene in human lung and colon cancer. Science 1998;282:284-7.
32. Martin ES, Cesari R, Pentimalli F, Yoder K, Fishel R, Himelstein AL, Martin SE, Godwin AK, Negrini M, Croce CM. The BCSC-1 locus at chromosome 11q23-q24 is a candidate tumor suppressor gene. Proc Natl Acad Sci USA 2003;100:11517-22.
33. Kuramochi M, Fukuhara H, Nobukuni T, Kanbe T, Maruyama T, Ghosh HP, Pletcher M, Isomura M, Onizuka M, Kitamura T, Sekiya T, Reeves RH, et al. TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet 2001;27:427-30.
34. Murakami Y. Involvement of a cell adhesion molecule. TSLC1/ IGSF4, in human oncogenesis. Cancer Sci 2005;96:543-52.
35. Jansen M, Fukushima N, Rosty C, Walter K, Altink R, Heek TV, Hruban R, Offerhaus JG, Goggins M. Aberrant methylation of the 50 CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanlNs. Cancer Biol Ther 2002; 1:293-6.
36. Fukuhara H, Kuramochi M, Fukami T, Kasahara K, Furuhata M, Nobukuni T, Maruyama T, Isogai K, Sekiya T, Shuin T, Kitamura T, Reeves RH, et al. Promoter methylation of TSLC1 and tumor suppression by its gene product in human prostate cancer. Jpn J Cancer Res 2002;93:605-9.
37. Honda T, Tamura G, Waki T, Jin Z, Sato K, Motoyama T, Kawata S, Kimura W, Nishizuka S, Murakami Y. Hypermethylation of the TSLC1 gene promoter in primary gastric cancers and gastric cancer cell lines. Jpn J Cancer Res 2002;93:857-60.
38. Yageta M, Kuramochi M, Masuda M, Fukami T, Fukuhara H, Maruyama T, Shibuya M, Murakami Y. Direct association of TSLC1 and DAL-1, two distinct tumor suppressor proteins in lung cancer. Cancer Res 2002;62:5129-33.
39. Tran YK, Bogler O, Gorse KM, Wieland I, Green MR, Newsham IF. A novel member of the NF2/ERM/4.1 superfamily with growth suppressing properties in lung cancer. Cancer Res 1999;59:35-43.
40. Jiang W, Newsham IF. The tumor suppressor DAL-1/4.1B and protein methylation cooperate in inducing apoptosis in MCF-7 breast cancer cells. Mol Cancer 2006;5:4.
41. Wong SY, Haack H, Kissil JL, Barry M, Bronson RT, Shen SS, Whittaker CA, Crowley D, Hynes RO. Protein 4.1B suppresses prostate cancer progression and metastasis. Proc Natl Acad Sci USA 2007;104:12784-9.
42. Chiang AK, Srivastava G, Lau PW, Ho FC. Differences in T-cell-receptor gene rearrangement and transcription in nasal lymphomas of natural killer and T-cell types: implications on cellular origin. Hum Pathol 1996;27:701-7.
43. Gao Z, Wang H, Pan Z. Investigation of the clinicopathologic features, immunophenotype and Epstein-Barr virus infection of the upper respiratory tract lymphomas in patients. Zhonghua Bing Li Xue Za Zhi 1998;27:251-4 (in Chinese).
44. Ying J, Li H, Murray P, Gao Z, Chen YW, Wang Y, Lee KY, Chan AT, Ambinder RF, Srivastava G, Tao Q. Tumor-specific methylation of the 8p22 tumor suppressor gene DLC1 is an epigenetic biomarker for Hodgkin, nasal NK/T-cell and other types of lymphomas. Epigenetics 2007;2:15-21.
45. Feng P, Ren EC, Liu D, Chan SH, Hu H. Expression of Epstein-Barr virus lytic gene BRLF1 in nasopharyngeal carcinoma: potential use in diagnosis. J Gen Virol 2000;81:2417-23.
46. Tao Q, Huang H, Geiman TM, Lim CY, Fu L, Qiu GH, Robertson KD. Defective de novo methylation of viral and cellular DNA sequences in ICF syndrome cells. Hum Mol Genet 2002;11:2091-102.
47. Ying J, Li H, Yu J, Ng KM, Poon FF, Wong SC, Chan AT, Sung JJ, Tao Q. WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer. Clin Cancer Res 2008;14:55-61.
48. Lee KY, Geng H, Ng KM, Yu J, van Hasselt A, Cao Y, Zeng YX, Wong AH, Wang X, Ying J, Srivastava G, Lung ML, Wang LD, Kwok TT, Levi BZ, Chan AT, Sung JJ, Tao Q. Epigenetic disruption of interferon-gamma response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomas. Oncogene 2008;27:5267-76.
49. Tao Q, Swinnen LJ, Yang J, Srivastava G, Robertson KD, Ambinder RF. Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR-based analysis. Am J Pathol 1999;155:619-25.
50. Qiu GH, Tan LK, Loh KS, Lim CY, Srivastava G, Tsai ST, Tsao SW, Tao Q. The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma. Oncogene 2004;23:4793-806.
51. Heller G, Fong KM, Girard L, Seidl S, End-Pfutzenreuter A, Lang G, Gazdar AF, Minna JD, Zielinski CC, Zochbauer-Muller S. Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas. Oncogene 2006;25:959-68.
52. Masuda M, Yageta M, Fukuhara H, Kuramochi M, Maruyama T, Nomoto A, Murakami Y. The tumor suppressor protein TSLC1 is involved in cell-cell adhesion. J Biol Chem 2002;277:31014-19.
53. Cavallaro U, Christofori G. Cell adhesion in tumor invasion and metastasis: loss of the glue is not enough. Biochim Biophys Acta 2001;1552:39-15.
54. Charboneau AL, Singh V, Yu T, Newsham IF. Suppression of growth and increased cellular attachment after expression of DAL-1 in MCF- 7 breast cancer cells. Int J Cancer 2002;100:181-8.
55. Lung HL, Cheung AK, Xie D, Cheng Y, Kwong FM, Murakami Y, Guan XY, Sham JS, Chua D, Protopopov AI, Zabarovsky ER, Tsao SW, Stanbridge EJ, Lung ML. TSLC1 is a tumor suppressor gene associated with metastasis in nasopharyngeal carcinoma. Cancer Res 2006;66:9385-92.